newsfilter
← Latest News
GlobeNewswire·

Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  • Syndax Pharmaceuticals appointed Aaron A. Ondrey as Chief Financial Officer effective November 9, 2026.
  • Ondrey received an inducement award to purchase up to 270,000 shares of common stock.
  • The stock option exercise price is set at $9.55 per share, matching the closing price on November 9, 2026.
  • The award vests over four years, with 25% vesting on the one-year anniversary & 1/48th vesting monthly thereafter for 36 months.
  • Continued service with Syndax is required for the award to vest through the applicable dates.
  • The Board approved the award as inducement material under NASDAQ Listing Rule 5635(c)(4).
  • Syndax is a commercial-stage biopharmaceutical company advancing cancer therapies including FDA-approved Revuforj® (revumenib) & Niktimvo™ (axatilimab-csfr).
Company
Syndax Pharmaceuticals, Inc.
Keywords
Nasdaq:SNDX, Syndax Pharmaceuticals, Inc.